Erlotinib Tablet, Film Coated
Product Images NDC 72485-219

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 72485-219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clin-1 (Cur 1)

A Kaplan-Meier survival curve graph titled 'Kaplan-Meier Curves of Investigator-Assessed PFS in Study 1,' showing progression-free survival probability over duration in months. The vertical axis represents progression-free survival probability from 0 to 1, and the horizontal axis shows duration in months from 0 to 45. Two survival curves are shown for chemotherapy and Erlotinib groups, with patient counts at risk listed below the graph at various time points.*

FDA Label Image

Clin-2 (Cur 2)

A Kaplan-Meier survival curve graph showing overall survival probability over 36 months for patients in Study 3, comparing treatment groups Erlotinib and Placebo. The y-axis represents survival probability from 0 to 1, and the x-axis shows overall survival in months. Patient risk numbers for each time point are listed below the graph.*

FDA Label Image

Cli-3 (Cur 3)

Kaplan-Meier survival curves illustrating overall survival probability over time in months for patients treated with Erlotinib compared to placebo in Study 4. The graph shows survival probability on the y-axis and overall survival in months on the x-axis, with patient numbers at risk displayed below for both treatment groups.*

FDA Label Image

Clin-4 (Cur 4)

A Kaplan-Meier survival curve chart displaying overall survival probability over time in months for a 100 mg cohort in Study 5. The graph compares survival probabilities between two groups, placebo and Erlotinib, with the number of patients at risk listed below the x-axis for each time point up to 36 months.*

FDA Label Image

Er-des (Des 1)

Chemical structure diagram of erlotinib hydrochloride, the active ingredient in the drug Erlotinib. The structure shows the molecular arrangement of atoms, including rings and functional groups characteristic of erlotinib.*

FDA Label Image

Erlt150 (Erl 150)

Box packaging label for Erlotinib Tablets 150 mg film-coated tablets by Armas Pharmaceuticals Inc. The label indicates each tablet contains 150 mg of erlotinib free base and includes a count of 30 tablets. Storage instructions specify keeping at 25°C with permitted excursions from 15° to 30°C. The label also provides manufacturer information as Shilpa Medicare Limited, India, and distributor details in New Jersey, USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.